Bliss GVS Pharma Ltd (BLISSGVS)
₹527.10
Mkt cap
₹5,457 Cr
P/E ratio
41.40
P/B
4.66
Div yield
0.29%
ROE
11.80%
ROCE
16.90%
EPS (TTM)
₹12.73
Book value
₹113
52W range
128–540
Sector
Healthcare
Incorporated in 1984, Bliss GVS Pharma Limited is engaged in manufacturing, marketing, trading and export of pharmaceutical formulations in the form of suppositories, pessaries, capsules, tablets, and syrups.
Health check
Constructive
ValuationFair
ProfitabilityAverage
GrowthModerate
TechnicalsBullish
52-week range
−2.32% from high₹527
₹128+312.12% from low₹540
Current
₹527.10
Prev close
₹525.75
Day
+0.26%
Price performance
1D
+0.26%
1W
+7.15%
1M
+19.89%
3M
+144.49%
6M
+216.14%
1Y
+254.47%
YTD
+223.73%
Financials
FRevenue, profit & margin
P/E ratio
41.4×
BLISSGVS is 19% above the sector median of 34.9×
BLISSGVS41.4×
Sector median34.9×
| Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Trend | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 185 | 160 | 212 | 201 | 198 | 184 | 218 | 210 | 198 | 207 | 244 | 218 | 257 | |
| Expenses | 179 | 135 | 158 | 157 | 170 | 149 | 176 | 181 | 177 | 166 | 201 | 183 | 213 | |
| Operating Profit | 6 | 24 | 54 | 44 | 28 | 34 | 41 | 30 | 21 | 41 | 43 | 35 | 44 | |
| OPM % | 3% | 15% | 26% | 22% | 14% | 19% | 19% | 14% | 11% | 20% | 18% | 16% | 17% | |
| Other Income | 3 | 5 | 13 | 5 | -24 | 4 | 5 | 15 | 12 | 35 | 8 | 16 | 11 | |
| Interest | 5 | 1 | 1 | 2 | 2 | 2 | 4 | 1 | 2 | 5 | 3 | 1 | 2 | |
| Depreciation | 5 | 6 | 6 | 7 | 7 | 7 | 7 | 8 | 8 | 8 | 8 | 8 | 9 | |
| Profit before tax | -1 | 22 | 59 | 40 | -4 | 30 | 36 | 36 | 23 | 63 | 41 | 41 | 45 | |
| Tax % | -561% | 34% | 27% | 27% | 24% | 26% | 28% | 29% | 29% | 30% | 30% | 39% | 18% | |
| Net Profit | 3 | 14 | 43 | 29 | -5 | 22 | 26 | 26 | 17 | 44 | 29 | 25 | 37 | |
| EPS in Rs | 0.32 | 1.41 | 4.05 | 2.64 | -0.87 | 1.97 | 2.31 | 2.26 | 1.47 | 4.08 | 2.58 | 2.20 | 3.36 | |
| Raw PDF |
Earnings
EResults dates & reactionsNo upcoming results date on calendar.
Fresh quarters land in the Financials table above, tagged NSE until screener catches up.
No reaction history yet.
No quarterly filings ingested yet.
Corporate actions
CLast 6 monthsNo recent corporate actions
Dividends, splits, and bonuses in the last six months show up here.
Shareholding
Sas of Mar 202635.36%Promoter
Promoters35.36%
FIIs10.45%4.09
DIIs5.04%0.74
Public49.15%4.83
Ownership trend
Peers
P8 companiesValuation vs quality
P/E × ROCE · bubble = market cap| Name | CMP | P/E | Mkt Cap | Div Yld | NP Qtr | Qtr Profit Var | Sales Qtr | Qtr Sales Var | ROCE |
|---|---|---|---|---|---|---|---|---|---|
| Sun Pharma.Inds. | ₹1,951.50 | 37.68 | 4,68,230 | 0.82% | 2,710 | +13.58% | 14,612 | +12.76% | 20.53% |
| Divi's Lab. | ₹7,273.00 | 73.61 | 1,93,075 | 0.41% | 751 | +13.44% | 2,831 | +9.52% | 21.96% |
| Torrent Pharma. | ₹5,017.80 | 77.49 | 1,69,825 | 0.76% | 364 | −20.58% | 4,197 | +41.84% | 15.19% |
| Cipla | ₹1,438.00 | 30.52 | 1,16,168 | 0.90% | 543 | −54.61% | 6,541 | −2.80% | 15.49% |
| Zydus Lifesci. | ₹1,156.90 | 21.27 | 1,15,401 | 0.09% | 1,341 | +21.92% | 7,587 | +16.22% | 21.14% |
| Lupin | ₹2,493.00 | 20.05 | 1,13,988 | 0.72% | 1,469 | +101.49% | 7,475 | +31.89% | 29.93% |
| Mankind Pharma | ₹2,543.10 | 52.28 | 1,05,029 | 0.04% | 559 | +34.23% | 3,443 | +11.81% | 13.50% |
| Bliss GVS Pharma | ₹514.50 | 41.40 | 5,457 | 0.29% | 37 | +128.90% | 257 | +29.80% | 16.93% |
| Median: 156 Co. | ₹434.68 | 34.87 | 2,006 | 0.08% | 12 | +22.43% | 177 | +16.46% | 15.19% |
Filings
DAnnual reports15
Financial Year 2026bseFinancial Year 2025bseFinancial Year 2024bseFinancial Year 2023bseFinancial Year 2022bseFinancial Year 2021bseFinancial Year 2020bseFinancial Year 2019bseFinancial Year 2018bseFinancial Year 2017bseFinancial Year 2016bseFinancial Year 2015bseFinancial Year 2014bseFinancial Year 2013bseFinancial Year 2012bse
Concall transcripts7
Credit ratings6
Announcements5
Shareholder Meeting / Postal Ballot-Scrutinizer''s Report 8h - 41st AGM voting results घोषित; ₹1 final dividend approved; Managing Director & CEO reappointed.Proceedings Of 41St Annual General Meeting Of Bliss GVS Pharma Limited 8h - 41st AGM held July 15, 2026; 100% final dividend approved, financials adopted, and MD reappointed.Contact Details Of Kmps For Reporting Of Material Events To Stock Exchanges 13h - Bliss GVS Pharma updated KMP contact details for material event disclosures under Regulation 30(5).Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS 7 Jul - The ESOP Allotment Committee of the Company at its meeting held today i.e. July 07, 2026 has approved the allotment of 1,87,750 equity shares of …Announcement under Regulation 30 (LODR)-Change in Management 3 Jul - Board appointed Santosh Parab as additional director; Rahul Adakmol becomes CEO from July 15, 2026; Narsimha Kamath steps aside as CEO.